专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060073153A1 Individualized anti-cancer antibodies 失效
公开(公告)号：US20060073153A1
公开(公告)日：2006-04-06
申请号：US11241721
申请日：2005-09-30
申请人： David Young , Miyoko Takahashi
发明人： David Young , Miyoko Takahashi
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： G01N33/6854 , A61K2039/505 , C07K16/00 , C07K16/30 , C07K2317/73 , G01N33/57484 , G01N2500/00
摘要： The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.

2. 发明申请

US20080019965A1 Individualized anti-cancer antibodies 审中-公开
标题翻译：个性化的抗癌抗体
公开(公告)号：US20080019965A1
公开(公告)日：2008-01-24
申请号：US11777551
申请日：2007-07-13
申请人： David Young , Miyoko Takahashi
发明人： David Young , Miyoko Takahashi
IPC分类号： A61K39/395 , C07K16/18 , G01N33/53
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/30 , C07K2317/73 , G01N33/57484 , G01N33/6854 , G01N2500/00
摘要： The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.
摘要翻译：本发明涉及使用新的筛选范例来生产患者特异性抗癌抗体的方法。通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可以为可用于治疗和诊断目的的个体患者定制抗癌抗体。本发明还涉及制备抗体的方法及其使用方法。抗体可以专门针对来自特定患者的一种肿瘤进行制备，并且基于它们的癌细胞细胞毒性和对非癌细胞同时缺乏毒性进行选择。抗体可用于帮助分期和诊断癌症，并可用于治疗肿瘤转移。抗癌抗体可以与从该患者获得的红细胞结合，并且基于认识到转移性癌症通常是良好血管化并且红细胞递送抗癌抗体可以具有将抗体集中在肿瘤部位的作用。

3. 发明申请

US20060240027A1 Individualized anti-cancer antibodies 失效
公开(公告)号：US20060240027A1
公开(公告)日：2006-10-26
申请号：US11387115
申请日：2006-03-22
申请人： David Young , Miyoko Takahashi
发明人： David Young , Miyoko Takahashi
IPC分类号： A61K39/395 , C12N5/06
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/30 , C07K2317/73 , G01N33/57484 , G01N33/6854 , G01N2500/00
摘要： The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.

4. 发明申请

US20060073144A1 Individualized anti-cancer antibodies 审中-公开
公开(公告)号：US20060073144A1
公开(公告)日：2006-04-06
申请号：US11240787
申请日：2005-09-30
申请人： David Young , Miyoko Takahashi
发明人： David Young , Miyoko Takahashi
IPC分类号： A61K39/395
CPC分类号： G01N33/6854 , A61K2039/505 , C07K16/00 , C07K16/30 , C07K2317/73 , G01N33/57484 , G01N2500/00
摘要： The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.

5. 发明授权

US5785966A Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients 失效
标题翻译：抑制人类异种或同种异体抗体以减少人类受体中异种移植物或同种异体移植排斥反应
公开(公告)号：US5785966A
公开(公告)日：1998-07-28
申请号：US261905
申请日：1994-06-15
申请人： John G. Coles , Miyoko Takahashi , David S. F. Young , Inka Brockhausen
发明人： John G. Coles , Miyoko Takahashi , David S. F. Young , Inka Brockhausen
IPC分类号： G01N33/53 , A61K38/00 , C07K16/42 , C12N15/02 , C12P21/08 , C12R1/91 , A61K39/395 , C12N5/12
CPC分类号： C07K16/4258 , A61K38/00
摘要： Reactivity between an alloantigen and an anti-alloantigen is indicative of immunological reactivity between two biological samples of the same species. Reactivity between a xenoantigen and an anti-xenoantigen is indicative of immunological reactivity between two biological samples of different species. In many cases both of the reactions are indicative of an antibody-mediated rejection. Anti-antibodies can be employed to reduce cross-reactivity in many transplantation-type situations, either within a similar species, or across species lines. These anti-antibodies are prepared against the antibodies responsible for the antibody-mediated rejection. These anti-antibodies can then be used in vivo or in vitro to complex with the antibodies thus reducing or eliminating reactivity between an alloantigen and an anti-alloantigen or reactivity between a xenoantigen and an anti-xenoantigen between any two species combinations. These antibodies may also be used to target and eliminate the B-cells that produce anti-xenogenic antibodies.
摘要翻译：同种异体抗原和抗同种异体抗原之间的反应性指示相同物种的两个生物样品之间的免疫反应性。异种抗原和抗异种抗原之间的反应性指示不同物种的两个生物样品之间的免疫反应性。在许多情况下，两种反应均表明抗体介导的排斥反应。可以使用抗抗体来减少许多移植类型的情况下的交叉反应性，不管是在相似的物种内还是在物种种类之间。针对负责抗体介导的排斥反应的抗体制备这些抗体。然后，这些抗体可以在体内或体外用于与抗体复合，从而减少或消除任何两种物种组合之间异种抗原和抗同种异体抗原之间的反应性或异种抗原与抗异种抗原之间的反应性。这些抗体也可用于靶向和消除产生抗异种抗体的B细胞。

6. 发明申请

US20070184507A1 Methods for predicting outcome in traumatic brain injury 审中-公开
标题翻译：预防创伤性脑损伤结局的方法
公开(公告)号：US20070184507A1
公开(公告)日：2007-08-09
申请号：US11737561
申请日：2007-04-19
申请人： George Jackowski , Eric Stanton , Petro Kupchak , Miyoko Takahashi , Michelle Davey
发明人： George Jackowski , Eric Stanton , Petro Kupchak , Miyoko Takahashi , Michelle Davey
IPC分类号： G01N33/53 , A61B6/00
CPC分类号： G01N33/6896 , A61B6/501 , G01N2333/988
摘要： The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients.
摘要翻译：本发明描述了通过评估通常与体液细胞损伤相关的标记物的水平来预测患有创伤性脑损伤（TBI）的患者的结果的方法。这种方法的使用改善了患有创伤性脑损伤的患者的诊断和治疗，从而可能最小化和/或消除这些患者的长期不良反应。

7. 发明授权

US06451547B1 Process for differential diagnosis of Alzheimer's dementia and device therefor 失效
标题翻译：阿尔茨海默氏痴呆的鉴别诊断过程及其设备
公开(公告)号：US06451547B1
公开(公告)日：2002-09-17
申请号：US09842079
申请日：2001-04-25
申请人： George Jackowski , Miyoko Takahashi
发明人： George Jackowski , Miyoko Takahashi
IPC分类号： C07K1618
CPC分类号： G01N33/6896 , C07K16/40 , C07K2317/20 , G01N33/573 , G01N2333/4709 , G01N2333/4727 , G01N2333/9015 , G01N2333/988 , G01N2800/2821
摘要： A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.
摘要翻译：公开了一种诊断阿尔茨海默氏病（AD）的方法。该方法包括直接检测生物化学标记物，特别是人谷氨酰胺合成酶在体液中，优选血液或血液制品中的存在。检测是通过掺入人谷氨酰胺合成酶特异性抗体的免疫测定法。另外，公开了用于区分AD和非AD痴呆的方法。

8. 发明授权

US07256272B2 Individualized anti-cancer antibodies 失效
标题翻译：个性化的抗癌抗体
公开(公告)号：US07256272B2
公开(公告)日：2007-08-14
申请号：US10713642
申请日：2003-11-13
申请人： David S. F. Young , Miyoko Takahashi
发明人： David S. F. Young , Miyoko Takahashi
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K39/00
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/30 , C07K2317/73 , G01N33/57484 , G01N33/6854 , G01N2500/00
摘要： The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells.
摘要翻译：本发明涉及使用新的筛选范例来生产患者特异性抗癌抗体的方法。通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可以为可用于治疗和诊断目的的个体患者定制抗癌抗体。本发明还涉及制备抗体的方法及其使用方法。抗体可以专门针对来自特定患者的一种肿瘤进行制备，并且基于它们的癌细胞细胞毒性和对非癌细胞同时缺乏毒性进行选择。

9. 发明授权

US07070945B2 Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment 失效
标题翻译：测定出轻度认知障碍患者单体脑相关人谷氨酰胺合成酶存在的方法
公开(公告)号：US07070945B2
公开(公告)日：2006-07-04
申请号：US10246383
申请日：2002-09-17
申请人： George Jackowski , Miyoko Takahashi
发明人： George Jackowski , Miyoko Takahashi
IPC分类号： G01N33/573 , G01N33/577 , G01N33/96 , C07K16/40
CPC分类号： C07K16/40 , C07K2317/20 , G01N33/573 , G01N33/6896 , G01N2333/4709 , G01N2333/4727 , G01N2333/9015 , G01N2333/988 , G01N2800/2821 , Y10S435/81 , Y10S435/975
摘要： A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.
摘要翻译：公开了一种确定患有轻度认知障碍（MCI）患有进展为阿尔茨海默病（AD）的可能性的患者的方法。该方法包括直接检测生物化学标记物，特别是人谷氨酰胺合成酶在体液中，优选血液或血液制品中的存在。检测是通过掺入人谷氨酰胺合成酶特异性抗体的免疫测定法。另外，公开了用于区分AD和非AD痴呆的方法。

10. 发明授权

US5702905A Monoclonal antibody to human ventricular myosin light chains 失效
标题翻译：人类心肌肌球蛋白轻链的单克隆抗体
公开(公告)号：US5702905A
公开(公告)日：1997-12-30
申请号：US314202
申请日：1994-09-28
申请人： Miyoko Takahashi , George Jackowski
发明人： Miyoko Takahashi , George Jackowski
IPC分类号： G01N33/53 , C07K16/18 , C12N5/10 , C12N15/02 , C12P21/08 , G01N33/577
CPC分类号： C07K16/18
摘要： A monoclonal antibody having high affinity to the cardiac isoform of human myosin light chains is described. The monoclonal antibody is prepared against a synthetic peptide from the amino terminal end of myosin light chain-1. The monoclonal antibody can be used as a reagent in an immunoassay system to identify blood, serum or plasma levels of myosin light chains. Such an immunoassay system can be used for diagnosing and quantifying myocardial necrosis and infarction.
摘要翻译：描述了对人肌球蛋白轻链的心脏同种型具有高亲和力的单克隆抗体。从肌球蛋白轻链-1的氨基末端制备针对合成肽的单克隆抗体。单克隆抗体可用作免疫测定系统中的试剂，以鉴定肌球蛋白轻链的血液，血清或血浆水平。这种免疫测定系统可用于诊断和定量心肌坏死和梗死。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式